Oral Epigallocatechin Gallate (EGCG) for Treatment of Alzheimer's Disease Induced Hearing Loss

Information

  • Research Project
  • 10288729
  • ApplicationId
    10288729
  • Core Project Number
    R01DC016835
  • Full Project Number
    3R01DC016835-03S1
  • Serial Number
    016835
  • FOA Number
    PA-18-591
  • Sub Project Id
  • Project Start Date
    6/1/2018 - 6 years ago
  • Project End Date
    5/31/2023 - a year ago
  • Program Officer Name
    FREEMAN, NANCY
  • Budget Start Date
    6/1/2020 - 4 years ago
  • Budget End Date
    5/31/2021 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    03
  • Suffix
    S1
  • Award Notice Date
    4/8/2021 - 3 years ago

Oral Epigallocatechin Gallate (EGCG) for Treatment of Alzheimer's Disease Induced Hearing Loss

Current Abstract - Supplement Recent data suggest an association between Alzheimer?s disease and hearing loss. Some reports suggest that amyloid ? (A?) deposition in the cochlea could account for the hearing loss. In transgenic mouse models of Alzheimer?s disease, it has been shown that the loss of hearing was associated with A? deposition in the cochlea. Previous studies from our laboratory indicate that A? increases Ca2+ and increased inflammatory markers in primary neuron cultures from rats. In addition, we observed that cortical tissues from 3xTg mouse model (also known as 3xTg-AD model) have increased levels of TNF-?. We speculate that a similar event occurs in the cochleae of Alzheimer?s disease mouse models which could contribute to hearing loss in these mice. Since our current RO1 proposal is based on the hypothesis that cochlear inflammation produces hearing loss, we believe that a Supplement on Alzheimer?s disease is within the general scope of the original grant. Therefore, experiments outlined in the supplement will test the hypothesis that Alzheimer?s transgenic mice show a time- dependent loss of hearing which is associated with A? accumulation in the cochlea. Specific aim 1 will explore the age-dependent loss of hearing in the 5XFAD mouse model covering the postnatal period 0 to 6 months during which these mice show amyloid deposition in the brain and cognitive deficits. Various inflammatory and apoptotic markers will be examined by immunohistochemical and real time PCR assays. Specific aim 2 will examine the effect of oral epigallocatechin gallate (EGCG), a natural product with antioxidant and anti- inflammatory properties, on the development of hearing loss in this mouse model. This drug shows promise for treatment of Alzheimer?s disease in preclinical trials. EGCG is currently being used in the current parent RO1 to treat cisplatin ototoxicity. It was shown to particularly effective for this indication. We believe this product stands a good chance in providing hearing protection in these animals and ultimately in humans suffering from Alzheimer?s-induced hearing loss.

IC Name
NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS
  • Activity
    R01
  • Administering IC
    DC
  • Application Type
    3
  • Direct Cost Amount
    250000
  • Indirect Cost Amount
    111744
  • Total Cost
    361744
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    173
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIA:361744\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    SOUTHERN ILLINOIS UNIVERSITY SCH OF MED
  • Organization Department
    PHARMACOLOGY
  • Organization DUNS
    038415006
  • Organization City
    SPRINGFIELD
  • Organization State
    IL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    627949616
  • Organization District
    UNITED STATES